Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Kashiwagi, Kenji

doi:10.1007/s10384-012-0139-2

Cited by 11 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SBP and DBP did not change significantly, and heart rate decreased significantly after switching from latanoprost to TTFC. The same results were shown in previous studies involving switching from latanoprost to fixed combinations of travoprost/timolol20 and from tafluprost to TTFC 5. This reduction in heart rate might be induced by timolol, a non-selective β-adrenergic antagonist,27 although in this study, this reduction did not lead to clinical problems such as dyspnea or difficulties in daily life.…”

Section: Discussionsupporting

confidence: 88%

“…Our results indicate no statistically significant change in SPK score after switching from latanoprost to TTFC. Furthermore, no significant change in SPK score was observed after switching from latanoprost to travoprost/timolol without BAC 20. These findings suggest that the deleterious effects of timolol may counter the reduction in cytotoxicity owing to reduced exposure to BAC.…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

Okumichi

Kiuchi

Baba³

et al. 2017

OPTH

View full text Add to dashboard Cite

PurposeTo evaluate the ocular-surface safety of a 0.001% benzalkonium chloride-containing tafluprost/timolol fixed combination (TTFC) in patients with primary open-angle glaucoma (POAG) or ocular hypertension who have inadequate intraocular pressure (IOP) control with latanoprost monotherapy.MethodsThis study is a multicenter, prospective, single-arm, open-label clinical study. Patients with POAG or ocular hypertension who have inadequate IOP control with latanoprost monotherapy were considered eligible. After providing informed consent, patients continued latanoprost monotherapy for 12 weeks, followed by a switch to TTFC. We evaluated the extent of ocular-surface damage using superficial punctate keratopathy (SPK) score, tear breakup time (TBUT), hyperemia score, IOP, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate at 0, 4, and 12 weeks after switching.ResultsA total of 68 patients were enrolled, of whom, 64 patients were included in the final analysis. No significant changes in SPK score, TBUT, or hyperemia score were observed at 4 and 12 weeks compared with week 0. IOP decreased significantly at 4 (13.9±2.5 mmHg) and 12 (14.1±2.5 mmHg) weeks, relative to week 0 (15.3±2.7 mmHg). No significant changes in either SBP or DBP were observed during the study, although patients’ mean heart rate decreased significantly after switching to TTFC. Adverse drug reactions to TTFC occurred in seven patients including two incidences of asthma and one of arrhythmia, and no events were serious.ConclusionThe ocular-surface safety of TTFC is not significantly different to that of latanoprost. Furthermore, switching from latanoprost to TTFC in patients with insufficient IOP control has additive IOP-lowering effects. TTFC is an effective approach for patients receiving latanoprost monotherapy who require more intensive IOP reduction.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 81%

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

Okumichi

Kiuchi

Baba³

et al. 2017

OPTH

View full text Add to dashboard Cite

show abstract

“…TRAVOTFC and BIMATOFC were compared to 0.005% latanoprost-0.5% timolol [26][27][28][29]. TRAVOTFC offers the potential benefits of increased patient adherence, reduced exposure to preservatives (now BAK-free), and reduced cost [30][31][32][33][34][35][36][37][38]. The aim of this study is to compare the efficacy of these fixed combinations.…”

Section: Introductionmentioning

confidence: 99%

Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and Travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma

Giuffrè¹

2012

OJOph

View full text Add to dashboard Cite

Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimatoprost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by naΐve open-angle glaucoma and IOP > 25 mmHg. Patients and Methods: Files from 70 patients (35 M, 35 F, mean age 69.52 y, S.D. 11.56, range: 37-87 y) in our Glaucoma Service were retrospectively analyzed as long as 12 months. Every subgroup, including 14 age-and sex-matched patients, was allocated to 1 of the 5 groups of the fixed combinations monotherapy. Data recorded after 3 months follow-up were statistically analyzed by descriptive and ANOVA statistics as percentage of IOP reduction from baseline. Results: All the fixed combinations were effective in lowering IOP. The mean percentage reduction was: brimonidine/timolol 43.57%, dorzolamide/timolol 37.67%, bimatoprost/timolol 35.60%, travoprost/timolol 33.25% and brinzolamide/timolol 23.0%. The brimonidine/timolol fixed combination showed to be statistically significant more effective only than brinzolamide/timolol fixed combination (p = 0.001). Setting the α error to 5%, the power of the study is 26%, phi: 0.842. Discussion: In all this cohort of patients the target IOP was successfully achieved. All the fixed combinations used in this study had a very good profile of efficacy. Brimonidine, dorzolamide, bimatoprost and travoprost/timolol fixed combinations statistically significantly reduced the percentage of IOP from baseline (p = 0.001) more than brinzolamide/timolol fixed combination.

show abstract

“…We are aware of only a limited number of antiglaucoma medication studies on Asian patients. 11 Ikeda et al 24 reported that nonresponders to latanoprost are more frequently Japanese, particularly in low-baseline patients with IOP. Thus, these nonresponders may be the cause of the differences between these studies.…”

Section: Discussionmentioning

confidence: 99%

Hypotensive Effect of Latanoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in NTG Patients: A Randomized, Multicenter, Crossover Clinical Trial

Shoji

Sato

Mizukawa³

et al. 2013

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Abstract: Compared to latanoprost monotherapy, TTFC therapy significantly reduced IOP and decreased the heart rate in the patient cohort. No differences were found in terms of patients' impressions.

Cited by 11 publications

References 27 publications

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study

Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and Travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma

Hypotensive Effect of Latanoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in NTG Patients: A Randomized, Multicenter, Crossover Clinical Trial

Contact Info

Product

Resources

About